We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
CALL
McDonald's
MCD
$190B
| $6K | 0.01% |
35,000
+22,500
| +180% | +$2.82M |
|
302
CALL
Perrigo
PRGO
$1.48B
| $6K | 0.01% |
+77,000
| New | +$7.98M |
|
303
PUT
Target
TGT
$63.4B
| $6K | 0.01% |
+5,000
| New | +$373K |
|
304
PUT
Verizon
VZ
$182B
| $6K | 0.01% |
15,000
| – | – |
|
|
N
305
CALL
DELISTED
Netsuite Inc
N
| $6K | 0.01% |
+10,000
| New | +$766K |
|
|
RPTP
306
PUT
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $6K | 0.01% |
+8,400
| New | +$43.1K |
|
|
BLUE
307
CALL
DELISTED
bluebird bio
BLUE
| $5K | ﹤0.01% |
1,992
-309
| -13% | -$175K |
|
308
Lipocine
LPCN
$18.4M
| $5K | ﹤0.01% |
+106
| New | +$16.4K |
|
309
CALL
Infosys
INFY
$46.5B
| $4K | ﹤0.01% |
93,600
-59,000
| -39% | -$552K |
|
|
310
PUT
Lipocine
LPCN
$18.4M
| $4K | ﹤0.01% |
+371
| New | +$57.5K |
|
311
CALL
Rigel Pharmaceuticals
RIGL
$750M
| $4K | ﹤0.01% |
+2,000
| New | +$49.7K |
|
|
CYTO
312
CALL
DELISTED
Altamira Therapeutics Ltd
CYTO
| – | – |
0
| – | – |
|
313
CALL
Home Depot
HD
$338B
| $3K | ﹤0.01% |
15,000
-5,000
| -25% | -$661K |
|
314
CALL
Illumina
ILMN
$28.2B
| $3K | ﹤0.01% |
10,280
| – | – |
|
|
315
PUT
Illumina
ILMN
$28.2B
| $3K | ﹤0.01% |
+9,149
| New | +$1.3M |
|
316
PUT
Kohl's
KSS
$1.96B
| $3K | ﹤0.01% |
+20,000
| New | +$795K |
|
|
SHPG
317
PUT
DELISTED
Shire pic
SHPG
| $3K | ﹤0.01% |
+4,200
| New | +$758K |
|
318
PUT
American Airlines Group
AAL
$9.91B
| $2K | ﹤0.01% |
+30,000
| New | +$1.01M |
|
319
PUT
Coca-Cola Europacific Partners
CCEP
$46.5B
| $2K | ﹤0.01% |
+400
| New | +$18.8K |
|
320
PUT
Colgate-Palmolive
CL
$74.4B
| $2K | ﹤0.01% |
+2,000
| New | +$142K |
|
321
PUT
Celldex Therapeutics
CLDX
$2.77B
| $2K | ﹤0.01% |
+333
| New | +$21.1K |
|
322
PUT
General Mills
GIS
$20.3B
| $2K | ﹤0.01% |
20,000
+7,500
| +60% | +$477K |
|
323
PUT
Hershey
HSY
$34.8B
| $2K | ﹤0.01% |
4,200
-11,000
| -72% | -$1.03M |
|
324
CALL
Insmed
INSM
$23.5B
| $2K | ﹤0.01% |
16,600
-5,000
| -23% | -$58.3K |
|
325
PUT
Kimberly-Clark
KMB
$36B
| $2K | ﹤0.01% |
2,500
-1,500
| -38% | -$196K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.